Protara Therapeutics, Inc.

NasdaqGM:TARA Stock Report

Market Cap: US$126.7m

Protara Therapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqGM:TARA Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
12 Sep 24SellUS$271,715Opaleye Management Inc.Company158,901US$1.71
10 Sep 24SellUS$114,251Opaleye Management Inc.Company61,992US$1.89
16 Jul 24SellUS$27,828Opaleye Management Inc.Company11,396US$2.44
11 Jul 24SellUS$175,842Opaleye Management Inc.Company74,551US$2.40
01 Jul 24SellUS$17,598Opaleye Management Inc.Company8,288US$2.12
28 Jun 24SellUS$142,503Opaleye Management Inc.Company64,568US$2.26
25 Jun 24SellUS$28,734Opaleye Management Inc.Company12,725US$2.26
31 May 24SellUS$44,008Opaleye Management Inc.Company15,054US$2.94
22 May 24SellUS$130,434Opaleye Management Inc.Company42,800US$3.06
17 May 24SellUS$230,326Opaleye Management Inc.Company70,885US$3.33
10 May 24SellUS$566,951Opaleye Management Inc.Company182,300US$3.11

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of TARA?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders1,570,1787.61%
Hedge Funds1,681,1548.15%
VC/PE Firms3,479,00016.9%
General Public6,928,09233.6%
Institutions6,971,34833.8%

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 81.5%.

Top Shareholders

Top 25 shareholders own 64.84% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
9.21%
RA Capital Management, L.P.
1,900,000US$11.7m0%0.13%
8.15%
Opaleye Management Inc.
1,681,154US$10.3m-27%1.56%
7.65%
Velan Capital Partners LP
1,579,000US$9.7m175%8.35%
4.57%
StemPoint Capital LP
942,857US$5.8m-4.19%1.76%
4.13%
Woodline Partners LP
851,567US$5.2m752%0.04%
4.01%
Jesse Shefferman
828,201US$5.1m-1.02%no data
3.93%
Tavistock Life Sciences
811,627US$5.0m0%0.32%
3.68%
The Vanguard Group, Inc.
759,612US$4.7m77.6%no data
3.3%
Citadel Advisors LLC
680,511US$4.2m2.28%no data
2.91%
Heights Capital Management, Inc.
600,380US$3.7m98.3%0.41%
2.84%
Randall Marshall
585,600US$3.6m0%no data
2.6%
Baker Bros. Advisors LP
536,832US$3.3m0%0.03%
1.63%
Renaissance Technologies LLC
336,740US$2.1m124%no data
0.9%
Two Sigma Investments, LP
185,223US$1.1m18.9%no data
0.87%
Oppenheimer Asset Management Inc.
179,125US$1.1m40.8%0.01%
0.82%
Geode Capital Management, LLC
170,040US$1.0m21%no data
0.75%
Ikarian Capital, LLC
155,712US$956.1k-13.8%0.25%
0.73%
Two Sigma Advisers, LP
151,618US$930.9k88.3%no data
0.57%
BlackRock, Inc.
116,977US$718.2k1.48%no data
0.37%
Marshall Wace LLP
77,351US$474.9k0%no data
0.31%
Jacqueline Zummo
63,331US$388.9k0%no data
0.24%
Bridgeway Capital Management, LLC
49,200US$302.1k103%no data
0.23%
Bailard, Inc.
47,132US$289.4k0%0.01%
0.22%
LPL Financial Corporation, Asset Management Arm
46,000US$282.4k4.55%no data
0.19%
BB&T Trust
40,000US$245.6k100%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/06 07:36
End of Day Share Price 2025/01/03 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Protara Therapeutics, Inc. is covered by 6 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Michael SchmidtGuggenheim Securities, LLC
Etzer DaroutGuggenheim Securities, LLC
Andrew FeinH.C. Wainwright & Co.